Why carry out this study?

A comparative efficacy analysis of the clinical benefits of biologic and oral treatments for moderate-to-severe plaque psoriasis can help inform treatment decisions when multiple therapeutic options are available.

This study assessed the short-term and long-term comparative efficacy of biologic and oral treatments for moderate-to-severe plaque psoriasis licensed by the US Food and Drug Administration or European Medicines Agency using data from their phase 2, 3, or 4 randomized controlled trials.

Psoriasis Area and Severity Index (PASI) 75/90/100 response rates at the end of the primary response period (short-term: 10–16 weeks from baseline) and the maintenance period (long-term: 48–52 weeks from baseline) were estimated using Bayesian network meta-analysis.

What was learned from the study?

In the short term (N = 71 trials), the PASI response rates were highest for ixekizumab, risankizumab, and brodalumab; in the long term (N = 11 trials), the PASI response rates were highest for risankizumab.

Ixekizumab, risankizumab, and brodalumab had the highest short-term efficacy, and risankizumab had the highest long-term efficacy.